Demographic and clinical characteristics of patients (N = 36)
| Characteristic . | N (%) . |
|---|---|
| Sex | |
| Female | 10 (27.8%) |
| Male | 26 (72.2%) |
| Age, median (range), y | 62.50 (31-77) |
| Stage | |
| Early stage | 8 (22.2%) |
| Advanced stage | 28 (77.8%) |
| ECOG PS category | |
| 0-1 | 25 (89.3%) |
| 2-3 | 3 (10.7%) |
| Unknown | 8 |
| IPI category | |
| 0-1(low risk) | 2 (5.7%) |
| 2-3 (low intermediate/high intermediate) | 7 (20%) |
| 4-5 (high risk) | 26 (74.3%) |
| Unknown | 1 |
| Histology | |
| DLBCL | 28 (77.8%) |
| B-cell lymphoma (unclassifiable) | 2 (5.6%) |
| Burkitt lymphoma | 3 (8.3%) |
| Plasmablastic lymphoma [both HIV (+)] | 2 (5.6%) |
| Other | 1 (2.8%) |
| MYC aberrancy | |
| DHL∗/THL† | 16 (44.4%) |
| DEL‡ | 7 (19.4%) |
| MYC single abnormality | 13 (36.1%) |
| Characteristic . | N (%) . |
|---|---|
| Sex | |
| Female | 10 (27.8%) |
| Male | 26 (72.2%) |
| Age, median (range), y | 62.50 (31-77) |
| Stage | |
| Early stage | 8 (22.2%) |
| Advanced stage | 28 (77.8%) |
| ECOG PS category | |
| 0-1 | 25 (89.3%) |
| 2-3 | 3 (10.7%) |
| Unknown | 8 |
| IPI category | |
| 0-1(low risk) | 2 (5.7%) |
| 2-3 (low intermediate/high intermediate) | 7 (20%) |
| 4-5 (high risk) | 26 (74.3%) |
| Unknown | 1 |
| Histology | |
| DLBCL | 28 (77.8%) |
| B-cell lymphoma (unclassifiable) | 2 (5.6%) |
| Burkitt lymphoma | 3 (8.3%) |
| Plasmablastic lymphoma [both HIV (+)] | 2 (5.6%) |
| Other | 1 (2.8%) |
| MYC aberrancy | |
| DHL∗/THL† | 16 (44.4%) |
| DEL‡ | 7 (19.4%) |
| MYC single abnormality | 13 (36.1%) |